MegaPro Biomedical Co., Ltd.

MegaPro Biomedical Co., Ltd. is a biotechnology company specializing in the research, development, and commercialization of nanotechnology-based pharmaceuticals. Founded in 2014 and headquartered in Hsinchu, Taiwan, the company employs proprietary nanoparticle and nanocell platforms to create next-generation drug candidates aimed at critical medical needs. MegaPro Biomedical focuses primarily on novel therapies for anemia linked to chronic kidney disease, iron deficiency, and oncological applications. Among its key investigational products are iron oxide nanoparticle injections for treating iron deficiency anemia, contrast agents for enhanced magnetic resonance imaging (MRI) of the liver and lymph nodes, and early-stage anti-cancer agents targeting solid tumors and metastases. The company operates within the healthcare sector, especially biotechnology and major pharmaceuticals, contributing to the advancement of nanomedicine in drug delivery, diagnostics, and cancer therapeutics. MegaPro Biomedical holds a distinct position in the market as an innovation-driven firm, aiming to address unmet patient needs through advanced nanotechnologies and targeted therapeutic development.